Clinical Trial

Kognitic’s AI Model Revolutionizes Primary Completion Date Predictions for Clinical Trials

A newly published study shows Kognitic's AI reduces clinical trial primary completion date prediction errors from 508 to 179 days,…

12 months ago

Suvoda and Greenphire to Merge Creating a Technology Platform Optimizing Clinical Trial Processes and Streamlining the Patient Journey

CONSHOHOCKEN, Pa. and KING OF PRUSSIA, Pa., Jan. 13, 2025 /PRNewswire/ -- Suvoda, a global clinical trial technology company specializing…

12 months ago

EMA Wellness Bolsters Executive Leadership to Support Growing Global Demand for a Singular Clinical Trial Data, Analytics and Adjudication Platform

New CEO, Chief Business Officer and Executive Advisors bring track records of driving growth and innovation in successful clinical trials…

12 months ago

Ainos Unveils AI Nose for Robotics: Invites Global Robotics Companies to Join Forces in Shaping the Future of Smell-Enabled Robots

Ainos invites robotics and humanoid companies to join Ainos Alliance and digitize smell SAN DIEGO, CA / ACCESSWIRE / January…

12 months ago

Sona Nanotech’s THT Cancer Therapy Preclinical Efficacy Studies Published In Peer-Reviewed Scientific Journal

Halifax, Nova Scotia--(Newsfile Corp. - January 13, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is…

12 months ago

Hemostemix Settlement via Depository Trust Company Plus OTCQB Update

Calgary, Alberta--(Newsfile Corp. - January 13, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company")…

12 months ago

Moderna Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited)Updates…

12 months ago

NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025

SHELTON, CT / ACCESSWIRE / January 13, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing…

12 months ago

NeurAxis Inc. Issues Letter to Shareholders

CARMEL, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology…

12 months ago

Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12

The first selective Fatty Acid Binding Protein 5 inhibitor safely administered to human subjects Initial safety and pharmacokinetic data expected…

12 months ago